• Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Asn771delinsPheHis (N771delinsFH); Zygosity=Unspecified (PubMed=29686424).
  

PubMed=29686424; DOI=10.1038/s41591-018-0007-9; PMCID=PMC5964608
Robichaux J.P., Elamin Y.Y., Tan Z., Carter B.W., Zhang S.-X., Liu S.-W., Li S., Chen T., Poteete A., Estrada-Bernal A., Le A.T., Truini A., Nilsson M.B., Sun H.-Y., Roarty E., Goldberg S.B., Brahmer J.R., Altan M., Lu C., Papadimitrakopoulou V., Politi K., Doebele R.C., Wong K.-K., Heymach J.V.
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Nat. Med. 24:638-646(2018)

PubMed=35820397; DOI=10.1016/j.ccell.2022.06.006; PMCID=PMC9667883
Elamin Y.Y., Robichaux J.P., Carter B.W., Altan M., Tran H., Gibbons D.L., Heeke S., Fossella F.V., Lam V.K., Le X.-N., Negrao M.V., Nilsson M.B., Patel A., Vijayan R.S.K., Cross J.B., Zhang J.-J., Byers L.A., Lu C., Cascone T., Feng L., Luthra R., San Lucas F.A., Mantha G., Routbort M.J., Blumenschein G.R. Jr., Tsao A.S., Heymach J.V.
Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Cancer Cell 40:754-767.e6(2022)